FDA Accepts Nanoscope's BLA for MOGENRY, a Potential First Gene-Agnostic RP Therapy — Nanoscope Therapeutics Inc.

Event summary

FDA accepted and filed Nanoscope's BLA for MOGENRY (sonpiretigene isteparvovec) for retinitis pigmentosa with severe vision loss.
BLA supported by positive Phase 2b/3 RESTORE trial data and long-term REMAIN study follow-up.
MOGENRY is a one-time, in-office optogenetic gene therapy requiring no genetic testing or surgery.
If approved, MOGENRY would be the first gene-agnostic treatment for RP with severe vision loss.
RESTORE trial met primary and key secondary endpoints, showing improvements in visual acuity.

The big picture

Nanoscope's BLA acceptance for MOGENRY marks a significant step in the development of gene-agnostic therapies for retinal degeneration. The FDA's filing comes at a time when optogenetic therapies are gaining traction as potential solutions for previously untreatable inherited retinal diseases. If approved, MOGENRY could set a new standard for RP treatment, particularly for patients with severe vision loss who lack current therapeutic options. The therapy's design for in-office administration could also expand access to treatment beyond specialized academic centers.

What we're watching

Regulatory Timeline: The pace at which the FDA will review the BLA and potential approval timeline for MOGENRY.
Market Adoption: Whether MOGENRY's non-surgical, in-office administration will facilitate broad adoption by community retina practices.
Long-Term Efficacy: The durability of MOGENRY's vision restoration effects as observed in the REMAIN long-term follow-up study.